Evidence map›Paper›PMID 32487146›Full record

ArticleBMC biotechnology2020

Colorectal cysts as a validating tool for CAR therapy.

Pierre Dillard, Maren Lie, Elizabeth Baken, Viola Hélène Lobert, Emmanuelle Benard, Hakan Köksal, Else Marit Inderberg, Sébastien Wälchli

Registry-linked trialAbstract read
In one paragraph

Article in BMC biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05401318 (Pilot Study for Ex Vivo Tailoring of Treatment in Colorectal Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05401318 recruitingnot on this mapstarted 2022, after this paper: background citation

Pilot Study for Ex Vivo Tailoring of Treatment in Colorectal Cancer

TypeobservationalSponsorUniversity Hospital, AkershusRan2022 to 2027Enrolled40ConditionsColorectal NeoplasmsArmsTumor tissue sampling for organoid development
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pierre DillardDepartment of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Maren LieDepartment of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Elizabeth BakenDepartment of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Viola Hélène LobertDepartment of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Emmanuelle BenardDepartment of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Hakan KöksalDepartment of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Else Marit InderbergDepartment of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Sébastien WälchliDepartment of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. sebastien.walchli@rr-research.no.ORCID 0000-0001-5869-1746

Funding

Norwegian Cancer Society 6829007Research Council of Norway 284983South-Eastern Norway Regional Health Authority 2016006UiO Life Science NA
6 · The paper itself

Abstract

backgroundTreatment of cancers has largely benefited from the development of immunotherapy. In particular, Chimeric Antigen Receptor (CAR) redirected T cells have demonstrated impressive efficacy against B-cell malignancies and continuous efforts are made to adapt this new therapy to solid tumors, where the immunosuppressive tumor microenvironment is a barrier for delivery. CAR T-cell validation relies on in vitro functional assays using monolayer or suspension cells and in vivo xenograft models in immunodeficient animals. However, the efficacy of CAR therapies remains difficult to predict with these systems, in particular when challenged against 3D organized solid tumors with highly intricate microenvironment. An increasing number of reports have now included an additional step in the development process in which redirected T cells are tested against tumor spheres.

resultsHere, we report a method to produce 3D structures, or cysts, out of a colorectal cancer cell line, Caco-2, which has the ability to form polarized spheroids as a validation tool for adoptive cell therapy in general. We used CD19CAR T cells to explore this method and we show that it can be adapted to various platforms including high resolution microscopy, bioluminescence assays and high-throughput live cell imaging systems.

conclusionWe developed an affordable, reliable and practical method to produce cysts to validate therapeutic CAR T cells. The integration of this additional layer between in vitro and in vivo studies could be an important tool in the pre-clinical workflow of cell-based immunotherapy.

Indexed as

B-LymphocytesCaco-2 CellsColorectal NeoplasmsCystsHeterograftsHumansImmunotherapyImmunotherapy, AdoptiveReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesTumor MicroenvironmentReceptors, Antigen, T-CellReceptors, Chimeric AntigenCAR T cellsImmunotherapyMicroscopySpheroids

Identifiers

PMID32487146
PMCPMC7268759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.